|
Acamprosate
resources
|
|
|
|
|
|
DRUG INFO
Acamprosate
Drug Name:
Acamprosate
Indication: For the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation
Pharmacology: Pharmacodynamic studies have shown that acamprosate calcium reduces alcohol intake in alcohol-dependent animals in a dose-dependent manner and that this effect appears to be specific to alcohol and the mechanisms of alcohol dependence. Acamprosate calcium has negligible observable central nervous system (CNS) activity in animals outside of its effects on alcohol dependence, exhibiting no anticonvulsant, antidepressant, or anxiolytic activity.
Mechanism Of Action: The mechanism of action of acamprosate in maintenance of alcohol abstinence is not completely understood. Chronic alcohol exposure is hypothesized to alter the normal balance between neuronal excitation and inhibition. in vitro and in vivo studies in animals have provided evidence to suggest acamprosate may interact with glutamate and GABA neurotransmitter systems centrally, and has led to the hypothesis that acamprosate restores this balance.
Drug Category: Alcohol Deterrents; ATC:N07BB03
Brand Names/Synonyms: Acamprosate; Acamprosate 6473; Acamprosate 6473 [Inn]; Acamprosato [Inn-Spanish]; Acamprosatum [Inn-Latin]; Campral; N-Acetylhomotaurine
Dosage Forms: Not Available
Absorption: Not Available
Interactions:
DrugBank: Interactions for Acamprosate
Interactions for Acamprosate:
The concomitant intake of alcohol and CAMPRAL does not affect the pharmacokinetics of either
alcohol or acamprosate.
Pharmacokinetic studies indicate that administration of disulfiram or diazepam does not affect the
pharmacokinetics of acamprosate. Co-administration of naltrexone with CAMPRAL produced a 25% increase in AUC
and a 33% increase in the Cmax of acamprosate. No adjustment of dosage is recommended in such
patients.
The pharmacokinetics of naltrexone and its major metabolite 6-beta-naltrexol were unaffected
following co-administration with CAMPRAL.
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with
CAMPRAL concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or non-opioid
analgesics was similar to that of subjects taking placebo with these concomitant medications. Patients taking
CAMPRAL concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared
with patients taking either medication alone.
Chemical IUPAC Name: 3-acetylaminopropane-1-sulfonicacid
Chemical Formula: C5H11NO4S
Half Life: 20 - 33 hours
Drug Type: Approved Drug
# Accession No: APRD00661
CAS Registry Number: 77337-76-9
|
|
|
|
|
|
Acamprosate News
(When available)
Forest Laboratories, Inc. and Cypress Bioscience, Inc. to Commence ... 05 Jan 2006
PR Newswire (press release), ...an angiotensin receptor blocker and diuretic combination product indicated for the second-line treatment of hypertension; Campral(R)*(acamprosate calcium), a ...
EU: EMEA to issue alcoholism treatment guidelines Dec 7, 2005
just-drinks.com, Existing treatments include Acamprosate, currently prescribed in the EU for preventing a recurrence of alcoholism, while other medicines are currently in ...
Finally, A Pill for Alcoholism? Dec 12, 2005
About - News & Issues, Another medication, acamprosate has proven to be more effective than naltrexone, but it has yet to be approved for use in the United States, although it has ...
How to Break the Chain Dec 10, 2005
Newsweek Last year the FDA approved a drug called acamprosate, which reduces craving by slowing the release of the chemical messenger glutamate. ...
NEW TECHNIQUE FOR ANEURYSM REPAIR HOLDS PROMISE FOR MANY Dec 14, 2005
Charlotte Sun-Herald, What was it? -- CH. ANSWER: Campral (acamprosate) adjusts the brain's messenger chemicals -- glutamine in particular -- and diminishes alcohol craving. ...
Mylan Laboratories and Forest Laboratories Announce Nebivolol ... Jan 12, 2006
PharmaLive.com (press release), ...an angiotensin receptor blocker and diuretic combination product indicated for the second- line treatment of hypertension; Campral(R) * (acamprosate calcium ...
Ask the Clinician: Answers to Readers' Questions Jan 9, 2006
About - News & Issues, Thanks, Rochelle. 2) Do you know of a product called Migraine Miracle (contains Campral) which its manufactures claim is FDA approved for migraine prevention? ...
Alkermes' Alcoholism Drug May See Strong Launch Jan 6, 2006
Forbes ..."Vivitrol could have a stronger than expected launch, if Campral is any indication". The analyst noted that the alcoholism drug Campral ...
Peanut butter, water may beat hangover Dec 27, 2005
Indianapolis Star, ...problem. They should talk with their doctor about medications (such as Antabuse, ReVia and Campral) that help people stop drinking. ...
Altered articles: NE Journal sues over phony Web claims Dec 23, 2005
The Patriot Ledger, The company also called the products Camptosar (Cancer Control) and Campral (Migraine Miracle). Camptosar is approved by the Food ...
NEW TECHNIQUE FOR ANEURYSM REPAIR HOLDS PROMISE FOR MANY Dec 14, 2005
Charlotte Sun-Herald, What was it? -- CH. ANSWER: Campral (acamprosate) adjusts the brain's messenger chemicals -- glutamine in particular -- and diminishes alcohol craving. ...
Cephalon Could See 2006 Sales Of $30M From Vivitrol Dec 29, 2005
Forbes ...considerable commercial appeal when compared to competitive products such as Forest Laboratories' (nyse: FRX - news - people ) Campral," which requires three ...
|
|
|
